Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating two different management protocols for children aged 1 to 12 years with severe traumatic brain injury sTBI in Latin America. The study aims to determine if using a treatment approach guided by invasive intracranial pressure ICP monitoring leads to better outcomes compared to a protocol based solely on imaging and clinical exams. This trial builds on previous adult studies and addresses the unique needs of pediatric patients to improve care and guide global clinical practice. The study randomly assigns children to one of two treatment groups. One group receives care following a protocol that uses invasive ICP monitoring to guide management decisions, based on recommendations from the Brain Trauma Foundation Guidelines. The other group follows the CREVICE protocol, which manages sTBI using imaging and clinical examination without ICP monitoring. Both protocols focus on aggressive management of sTBI. The trial is conducted in eight pediatric intensive care units in Latin America, aiming to strengthen research skills among local pediatric intensivists. Participants will be closely monitored during their hospital stay, with the study measuring outcomes such as quality of life using the Pediatric Quality of Life Inventory PedsQL at three and six months, functional recovery with the Glasgow Outcome Scale - Extended Pediatric GOS-E Peds, mortality rates, brain-specific treatments, and length of stay in intensive care. Data will be collected for up to six months after injury to assess the effects of the two management strategies on recovery and complications.
Actively Recruiting
This research aims to evaluate the long-term efficacy and safety of ianalumab treatment in adults with lupus nephritis who have completed the SIRIUS-LN core study. The study focuses on two groups patients who achieved complete or partial renal response and stopped study treatment, and those who continue or start open-label ianalumab because they did not meet response criteria or were already receiving it. This open-label extension can last up to six years. Participants are divided into two cohorts. Cohort 1 includes patients who responded to previous treatment and will withdraw from the study drug while continuing standard care, with the option to restart ianalumab if they experience renal flare. Cohort 2 includes patients who did not respond or were already on open-label ianalumab and will continue receiving this treatment during the extension. The study allows investigators to decide if continuing in the extension is beneficial for each participant. Throughout the study, participants will be monitored for kidney flare-ups, changes in immunosuppressive medication, adverse events, and the presence of antibodies against ianalumab. Assessments include safety and efficacy measures over up to six years, with the primary outcomes focusing on time to renal flare or adverse events depending on the cohort. Participants will have regular evaluations to track their health status and treatment effects during this period.